Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs for cancer, said today it has hired its first head of commercial operations to prepare for the introduction of what it hopes will be its first marketed product. The company (NASDAQ: [[ticker:SGEN]]) said it hired Bruce Seeley for the new position of executive vice president, commercial. Seeley will be responsible for building up the sales and marketing teams to support brentuximab vedotin, which the company expects to the U.S. market by late 2011. Seeley previously worked at Genentech as senior director for marketing of trastuzumab (Herceptin) and TDM1.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
